Corporate Governance

Prostatype Genomics AB (the “Company”) is a public company, registered in Sweden, with organization number 556726-0285 and its Legal Entity Identifier (LEI) is 549300JO6MPCGPVHVU91. The Company was formed and registered with the Swedish Companies Registration Office (Bolagsverket) on 12 March 2007 and was up until 6 July 2020 operating under the name Chundsell Medicals AB.

The Company is governed by Swedish legislation, mainly the Swedish Companies Act (2005:551) and the Swedish Annual Accounts Act (1995:1554). Following the listing of the Company’s shares on Nasdaq First North Growth Market, the Company abides by the First North Growth Market’s rulebook. In addition to existing legislation and the First North Growth Market’s Rulebook, the Company’s Articles of Association and internal guidelines for corporate governance form the basis for the Company’s corporate governance. The Articles of Association contain, for example, the seat of the Board of Directors, the focus of the Company’s business activities, the limits for the share capital and number of shares and the conditions for participation at general meetings.

The company’s board is located in Stockholm, Sweden.